KeyCorp vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? KeyCorp trades at $20.01 (market cap $21.45B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.96 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is the larger of the two by market cap, and KeyCorp pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| KEY | RPRX | |
|---|---|---|
Market Cap | $21.45B | $25.27B |
Volume | 19,450,846 | 3,671,183 |
Sector | Financials | Health |
52-Week High | $23.99 | $63.96 |
52-Week Low | $16.78 | $35.44 |
Typical Hold Time | 66 Days | 1 Days |
Enterprise Value | $34.63B | $32.50B |
Dividend Yield | 4.08% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.985, up 0.78% on the day, with strong fundamental metrics including a P/E of 11.75 and net income margin of 26.72%. The stock shows consistent earnings beats in recent quarters and maintains a solid dividend yield. Technical indicators suggest bearish momentum despite neutral oscillators, while analyst consensus remains strongly bullish with a $25.00 price target representing 25% upside potential from current levels.
KEY presents a compelling value opportunity with attractive valuation multiples and strong profitability, though technical weakness and frozen dividend payments pose near-term concerns. The bank's improved revenue guidance for 2026 and aggressive share buyback program support EPS growth, while interest rate sensitivity remains a key risk factor for the regional banking sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →